Knee tuberculosis under rituximab therapy for rheumatoid arthritis

Joint Bone Spine

Volumn 80, Issue 4, 2013, Pages 435-436

  Ottaviani, Sébastien ^a   Tiendrebeogo, Joelle ^a   Choudat, Laurence ^a   Gill, Ghislaine ^a   Palazzo, Elisabeth ^a   Meyer, Olivier ^a   Dieudé, Philippe ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ETHAMBUTOL; ISONIAZID; METHOTREXATE; PYRAZINAMIDE; RIFAMPICIN; RITUXIMAB;

ADULT; BACTERIUM DETECTION; BLOOD CELL COUNT; CAMBODIAN; CASE REPORT; DAS28; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; FEVER; GRANULOMA; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; JOINT BIOPSY; JOINT EFFUSION; LAVAGE; LETTER; LYMPHOCYTE COUNT; MYCOBACTERIUM TUBERCULOSIS; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; POPLITEAL CYST; RELAPSE; RHEUMATOID ARTHRITIS; SKIN FISTULA; SWELLING; SYNOVIAL FLUID; TUBERCULOUS ARTHRITIS; TUBERCULOUS GONITIS;

EID: 84880331443     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.10.018     Document Type: Letter

References (9)

1. Gardam M.A., Keystone E.C., Menzies R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003, 3:148-155.
2. Nam J.L., Winthrop K.L., van Vollenhoven R.F., et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010, 69:976-986.
3. Singh J.A., Furst D.E., Bharat A., et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012, 64:625-639.
4. Smolen J.S., Keystone E.C., Emery P., et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66:143-150.
5. Pham T., Fautrel B., Gottenberg J.E., et al. Rituximab (MabThera) therapy and safety management. Clinical tool guide. Joint Bone Spine 2008, 75:S1-S99.
6. Wallis R.S. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008, 8:601-611.
7. Jick S.S., Lieberman E.S., Rahman M.U., et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006, 55:19-26.
8. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005, 31:456-473.
9. Salliot C., van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009, 68:1100-1104.